Defense Metals Corp. (DFMTF)

Theseus Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Selling, General & Admin	3.04	2.49	2.9	2.34	1.94
Operating Expenses	4.06	3.12	3.9	3.88	2.6
Operating Income	-4.06	-3.12	-3.9	-3.88	-2.6
Interest Expense	-0.61	-	-	-	-
Interest & Investment Income	0	0.12	-	-	-
Other Non Operating Income (Expenses)	-1.1	0.24	1.19	0.1	-0.04
Pretax Income	-5.77	-2.76	-2.71	-3.78	-2.64
Net Income	-5.77	-2.76	-2.71	-3.78	-2.64
Net Income to Common	-5.77	-2.76	-2.71	-3.78	-2.64
Shares Outstanding (Basic)	260	249	178	96	53
Shares Outstanding (Diluted)	260	249	178	96	53
Shares Change (YoY)	4.21%	39.60%	86.06%	81.04%	68.05%
EPS (Basic)	-0.02	-0.01	-0.02	-0.04	-0.05
EPS (Diluted)	-0.02	-0.01	-0.02	-0.04	-0.05
Free Cash Flow	-4.04	-12.73	-9.87	-5.31	-3.53
Free Cash Flow Per Share	-0.02	-0.05	-0.06	-0.06	-0.07
EBITDA	-4	-	-	-	-
D&A For EBITDA	0.06	-	-	-	-
EBIT	-4.06	-3.12	-3.9	-3.88	-2.6

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.